Therapy for patients with CKD and low bone mineral density

Nature Reviews Nephrology

Volumn 9, Issue 11, 2013, Pages 681-692

  Ott, Susan M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DENOSUMAB; ESTROGEN; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PHOSPHATE; PLACEBO; RALOXIFENE; TESTOSTERONE; VITAMIN D;

BLOOD VESSEL CALCIFICATION; BONE DENSITY; CHRONIC KIDNEY DISEASE; EXERCISE; FALLING; HUMAN; NUTRITION; OSSIFICATION; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; UPREGULATION;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; HUMANS; OSTEOPOROSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84890807205     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2013.182     Document Type: Review

References (122)

1. Pendras, J. P. & Erickson, R. V. Hemodialysis: A successful therapy for chronic uremia. Ann. Intern. Med. 64, 293-311 (1966).
2. Fahrleitner-Pammer, A. et al. Bone markers predict cardiovascular events in chronic kidney disease. J. Bone Miner. Res. 23, 1850-1858 (2008).
3. Alem, A. M. et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int. 58, 396-399 (2000).
4. Mitterbauer, C., Kramar, R. & Oberbauer, R. Age and sex are sufficient for predicting fractures occurring within 1 year of hemodialysis treatment. Bone 40, 516-521 (2007).
5. Jamal, S. A., Leiter, R. E., Jassal, V., Hamilton, C. J. & Bauer, D. C. Impaired muscle strength is associated with fractures in hemodialysis patients. Osteoporos. Int. 17, 1390-1397 (2006).
6. Dooley, A. C., Weiss, N. S. & Kestenbaum, B. Increased risk of hip fracture among men with CKD. Am. J. Kidney Dis. 51, 38-44 (2008).
7. Dukas, L., Schacht, E. & Stahelin, H. B. In elderly men and women treated for osteoporosis a low creatinine clearance of <65 ml/min is a risk factor for falls and fractures. Osteoporos. Int. 16, 1683-1690 (2005).
8. Ensrud, K. E. et al. Renal function and risk of hip and vertebral fractures in older women. Arch. Intern. Med. 167, 133-139 (2007).
9. LaCroix, A. Z. et al. Cystatin C, renal function and incidence of hip fracture in postmenopausal women. J. Am. Soc. Geriat. 56, 1434-1441 (2008).
10. Malluche, H. H., Mawad, H. W. & Monier-Faugere, M. C. Renal osteodystrophy in the first decade of the new millennium: Analysis of 630 bone biopsies in black and white patients. J. Bone Miner. Res. 26, 1368-1376 (2011).
11. Cejka, D. et al. Sclerostin and Dickkopf 1 in renal osteodystrophy. Clin. J. Am. Soc. Nephrol. 6, 877-882 (2011).
12. Lavi-Moshayoff, V., Wasserman, G., Meir, T., Silver, J. & Naveh-Many, T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: A bone parathyroid feedback loop. Am. J. Physiol. Renal Physiol. 299, F882-F889 (2010).
13. KDIGO. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. Suppl. 113, S1-S130 (2009).
14. Evolve Investigators. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N. Engl. J. Med. 367, 2482-2494 (2012).
15. Klawansky, S. et al. Relationship between age, renal function and bone mineral density in the US population. Osteoporos. Int. 14, 570-576 (2003).
16. Hsu, C. Y., Cummings, S. R., McCulloch, C. E. & Chertow, G. M. Bone mineral density is not diminished by mild to moderate chronic renal insufficiency. Kidney Int. 61, 1814-1820 (2002).
17. Ott, S M. Review article: Bone density in patients with chronic kidney disease stages 4-5 Nephrology (Carlton) 14, 395-403 (2009).
18. Miller, P. D. et al. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: A pooled analysis of nine clinical trials. J. Bone Miner. Res. 20, 2105-2115 (2005).
19. Jamal, S. A. et al. Alendronate treatment in women with normal to severely impaired renal function: An analysis of the Fracture Intervention Trial. J. Bone Miner. Res. 22, 503-508 (2007).
20. Ishani, A., Blackwell, T., Jamal, S. A., Cummings, S. R. & Ensrud, K. E. The effect of raloxifene treatment in postmenopausal women with CKD. J. Am. Soc. Nephrol. 19, 1430-1438 (2008).
21. Miller, P. D., Schwartz, E. N., Chen, P., Misurski, D. A. & Krege, J. H. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos. Int. 18, 59-68 (2007).
22. Anderson, G. L. et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 291, 1701-1712 (2004).
23. Rossouw, J. E. et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288, 321-333 (2002).
24. Manson, J. E. et al. Estrogen therapy and coronary-artery calcification. N. Engl. J. Med. 356, 2591-2602 (2007).
25. Matuszkiewicz-Rowinska, J. et al. The benefits of hormone replacement therapy in pre-menopausal women with oestrogen deficiency on haemodialysis. Nephrol. Dial. Transplant. 14, 1238-1243 (1999).
26. Stehman-Breen, C., Anderson, G., Gibson, D., Kausz, A. T. & Ott, S. Pharmacokinetics of oral micronized beta-estradiol in postmenopausal women receiving maintenance hemodialysis. Kidney Int. 64, 290-294 (2003).
27. Albaaj, F. et al. Prevalence of hypogonadism in male patients with renal failure. Postgrad. Med. J. 82, 693-696 (2006).
28. Guevara, A. et al. Serum gonadotropin and testosterone levels in uremic males undergoing intermittent dialysis. Metabolism 18, 1062-1066 (1969).
29. Ott, S. M., Oleksik, A., Lu, Y., Harper, K. & Lips, P. Bone histomorphometric and biochemical marker results of a 2 year placebo-controlled trial of raloxifene in postmenopausal women. J. Bone Miner. Res. 17, 341-348 (2002).
30. Cummings, S. R. et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281, 2189-2197 (1999).
31. Zanchetta, J. R. & Bogado, C. E. Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism. J. Bone Miner. Res. 16, 189-190 (2001).
32. Eriguchi, R., Umakoshi, J., Miura, S. & Sato, Y. Raloxifene ameliorates progressive bone loss in postmenopausal dialysis patients with controlled parathyroid hormone levels. Clin. Nephrol. 72, 423-429 (2009).
33. Melamed, M. L. et al. Raloxifene, a selective estrogen receptor modulator, is renoprotective: A post-hoc analysis. Kidney Int. 79, 241-249 (2011).
34. Hernandez, E. et al. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney Int. 63, 2269-2274 (2003).
35. Tanaka, M. et al. Effects of raloxifene on bone mineral metabolism in postmenopausal Japanese women on hemodialysis. Ther. Apher. Dial. 15 (Suppl. 1), 62-66 (2011).
36. Bilezikian, J. P. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. Am. J. Med. 122, S14-S21 (2009).
37. Chavassieux, P. M. et al. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J. Clin. Invest. 100, 1475-1480 (1997).
38. Eriksen, E. F., Melsen, F., Sod, E., Barton, I. & Chines, A. Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 31, 620-625 (2002).
39. Boivin, G. & Meunier, P. J. Effects of bisphosphonates on matrix mineralization. J. Musculoskelet. Neuronal. Interact. 2, 538-543 (2002).
40. Borah, B. et al. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: Sequential triple biopsy studies with micro-computed tomography. Bone 39, 345-352 (2006).
41. Bauer, D. C. et al. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: The fracture intervention trial. J. Bone Miner. Res. 21, 292-299 (2006).
42. Whyte, M. P. et al. Enzyme-replacement therapy in life-threatening hypophosphatasia. N. Engl. J. Med. 366, 904-913 (2012).
43. Russell, R. G., Watts, N. B., Ebetino, F. H. & Rogers, M. J. Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy. Osteoporos. Int. 19, 733-759 (2008).
44. Gibbs, C. J., Aaron, J. E. & Peacock, M. Osteomalacia in Paget's disease treated with short term, high dose sodium etidronate. Br. Med. J. (Clin. Res. Ed.) 292, 1227-1229 (1986).
45. Otero, J. E. et al. Severe skeletal toxicity from protracted etidronate therapy for generalized arterial calcification of infancy. J. Bone Miner. Res. 28, 419-430 (2013).
46. Recker, R. R. et al. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J. Bone Miner. Res. 23, 6-16 (2008).
47. Dell, R. M. et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J. Bone Miner. Res. 27, 2544-2550 (2012).
48. Barreto, F. C. et al. Osteoporosis in hemodialysis patients revisited by bone histomorphometry: A new insight into an old problem. Kidney Int. 69, 1852-1857 (2006).
49. Chavassieux, P. et al. Bone histomorphometry of transiliac paired bone biopsies after 6 or 12 months of treatment with oral strontium ranelate in 387 osteoporotic women. Randomized comparison to alendronate. J. Bone Miner. Res. http://dx.doi.org/10.1002/jbmr.2074.
50. Perazella, M. A. & Markowitz, G. S. Bisphosphonate nephrotoxicity. Kidney Int. 74, 1385-1393 (2008).
51. Lin, J. H. Bisphosphonates: A review of their pharmacokinetic properties. Bone 18, 75-85 (1996).
52. Buttazzoni, M. et al. Elimination and clearance of pamidronate by haemodialysis. Nephrology (Carlton) 11, 197-200 (2006).
53. Amerling, R., Harbord, N. B., Pullman, J. & Feinfeld, D. A. Bisphosphonate use in chronic kidney disease: Association with adynamic bone disease in a bone histology series. Blood Purif. 29, 293-299 (2010).
54. Lu, K. C., Yeung, L. K., Lin, S. H., Lin, Y. F. & Chu, P. Acute effect of pamidronate on PTH secretion in postmenopausal hemodialysis patients with secondary hyperparathyroidism. Am. J. Kidney Dis. 42, 1221-1227 (2003).
55. Torregrosa, J. V., Moreno, A., Mas, M., Ybarra, J. & Fuster, D. Usefulness of pamidronate in severe secondary hyperparathyroidism in patients undergoing hemodialysis. Kidney Int. Suppl. 85, S88-S90 (2003).
56. Bergner, R. et al. Treatment of reduced bone density with ibandronate in dialysis patients. J. Nephrol. 21, 510-516 (2008).
57. Mitsopoulos, E. et al. Impact of long-term cinacalcet, ibandronate or teriparatide therapy on bone mineral density of hemodialysis patients: A pilot study. Am. J. Nephrol. 36, 238-244 (2012).
58. Toussaint, N. D., Lau, K. K., Strauss, B. J., Polkinghorne, K. R. & Kerr, P. G. Effect of alendronate on vascular calcification in CKD stages 3 and 4: A pilot randomized controlled trial. Am. J. Kidney Dis. 56, 57-68 (2010).
59. Giachelli, C. M. The emerging role of phosphate in vascular calcification. Kidney Int. 75, 890-897 (2009).
60. Shanahan, C. M., Crouthamel, M. H., Kapustin, A. & Giachelli, C. M. Arterial calcification in chronic kidney disease: Key roles for calcium and phosphate. Circ. Res. 109, 697-711 (2011).
61. Silberstein, E. B., Clark, R. A. & DeLong, S. Clinical and radiographic correlates of femoral artery visualization on bone scan. Int. J. Rad. Appl. Instrum. B 16, 709-713 (1989).
62. Tamura, K. et al. Prevention of aortic calcification by etidronate in the renal failure rat model. Eur. J. Pharmacol. 558, 159-166 (2007).
63. Ariyoshi, T., Eishi, K., Sakamoto, I., Matsukuma, S. & Odate, T. Effect of etidronic acid on arterial calcification in dialysis patients. Clin. Drug Investig. 26, 215-222 (2006).
64. Tankó, L. B., Qin, G., Alexandersen, P., Bagger, Y. Z. & Christiansen, C. Effective doses of ibandronate do not influence the 3 year progression of aortic calcification in elderly osteoporotic women. Osteoporos. Int. 16, 184-190 (2005).
65. Hill, J. A. et al. Progression of coronary artery calcification in patients taking alendronate for osteoporosis. Acad. Radiol. 9, 1148-1152 (2002).
66. Harris, S. T. Bisphosphonate therapy and vascular calcification. JAMA 283, 1424-1425 (2000).
67. Black, D. M. et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. 356, 1809-1822 (2007).
68. Schousboe, J. T. et al. Abdominal aortic calcification detected on lateral spine images from a bone densitometer predicts incident myocardial infarction or stroke in older women. J. Bone Miner. Res. 23, 409-416 (2008).
69. Kang, J. H., Keller, J. J. & Lin, H. C. Bisphosphonates reduced the risk of acute myocardial infarction: A 2 year follow-up study. Osteoporos. Int. 24, 271-277 (2013).
70. Lu, P. Y., Hsieh, C. F., Tsai, Y. W. & Huang, W. F. Alendronate and raloxifene use related to cardiovascular diseases: Differentiation by different dosing regimens of alendronate. Clin. Ther. 33, 1173-1179 (2011).
71. Vestergaard, P. Acute myocardial infarction and atherosclerosis of the coronary arteries in patients treated with drugs against osteoporosis: Calcium in the vessels and not the bones? Calcif. Tissue Int. 90, 22-29 (2012).
72. Wolfe, F. et al. Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis. J. Bone Miner. Res. 28, 984-991 (2013).
73. Hartle, J. E. et al. Bisphosphonate therapy, death, and cardiovascular events among female patients with CKD: A retrospective cohort study. Am. J. Kidney Dis. 59, 636-644 (2012).
74. London, G. M. et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J. Am. Soc. Nephrol. 15, 1943-1951 (2004).
75. Tomiyama, C. et al. Coronary calcification is associated with lower bone formation rate in CKD patients not yet in dialysis treatment. J. Bone Miner. Res. 25, 499-504 (2010).
76. Barreto, D. V. et al. Association of changes in bone remodeling and coronary calcification in hemodialysis patients: A prospective study. Am. J. Kidney Dis. 52, 1139-1150 (2008).
77. Asci, G. et al. The link between bone and coronary calcifications in CKD 5 patients on haemodialysis. Nephrol. Dial. Transplant. 26, 1010-1015 (2011).
78. Cannata-Andia, J. B., Roman-Garcia, P. & Hruska, K. The connections between vascular calcification and bone health. Nephrol. Dial. Transplant. 26, 3429-3436 (2011).
79. Ott, S. M. Bisphosphonate safety and efficacy in chronic kidney disease. Kidney Int. 82, 833-835 (2012).
80. Cejka, D., Kodras, K., Bader, T. & Haas, M. Treatment of hemodialysis-associated adynamic bone disease with teriparatide (PTH(1-34): A pilot study. Kidney Blood Press. Res. 33, 221-226 (2010).
81. Reid, I. et al. Effects of denosumab on bone histomorphometry: The freedom and stand studies. J. Bone Miner. Res. 25, 2256-2265 (2010).
82. Bone, H. G. et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J. Clin. Endocrinol. Metab. 96, 972-980 (2011).
83. Jamal, S. A. et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J. Bone Miner. Res. 26, 1829-1835 (2011).
84. Block, G. A., Bone, H. G., Fang, L., Lee, E. & Padhi, D. A single-dose study of denosumab in patients with various degrees of renal impairment. J. Bone Miner. Res. 27, 1471-1479 (2012).
85. McCormick, B. B., Davis, J. & Burns, K. D. Severe hypocalcemia following denosumab injection in a hemodialysis patient. Am. J. Kidney Dis. 60, 626-628 (2012).
86. Ungprasert, P., Cheungpasitporn, W., Srivali, N., Kittanamongkolchai, W. & Bischof, E. F. Life-threatening hypocalcemia associated with denosumab in a patient with moderate renal insufficiency. Am. J. Emerg. Med. 31, 756.e1-756.e2 (2013).
87. Qi, W. X., Tang, L. N., He, A. N., Yao, Y. & Shen, Z. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: A meta-analysis of seven randomized controlled trials. Int. J. Clin. Oncol. http://dx.doi.org/10.1007/s10147 013 0561-0566.
88. Lam, S. & Zouzias, K. Strontium ranelate for the management of osteoporosis. Consult. Pharm. 23, 531-537 (2008).
89. Oste, L. et al. Time-evolution and reversibility of strontium-induced osteomalacia in chronic renal failure rats. Kidney Int. 67, 920-930 (2005).
90. Yang, Q., Jian, J., Abramson, S. B. & Huang, X. Inhibitory effects of iron on bone morphogenetic protein 2 induced osteoblastogenesis. J. Bone Miner. Res. 26, 1188-1196 (2011).
91. Schrooten, I. et al. Dose-dependent effects of strontium on bone of chronic renal failure rats. Kidney Int. 63, 927-935 (2003).
92. D'Haese, P. C. et al. Increased bone strontium levels in hemodialysis patients with osteomalacia. Kidney Int. 57, 1107-1114 (2000).
93. Cohen-Solal, M. Strontium overload and toxicity: Impact on renal osteodystrophy. Nephrol. Dial. Transplant. 17 (Suppl. 2), 30-34 (2002).
94. Doublier, A. et al. Distribution of strontium and mineralization in iliac bone biopsies from osteoporotic women treated long-term with strontium ranelate. Eur. J. Endocrinol. 165, 469-476 (2011).
95. O'Donnell, S., Cranney, A., Wells, G. A., Adachi, J. D. & Reginster, J Y. Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database of Systematic Reviews, Issue 3. Art. No.: CD005326. http://dx.doi.org/10.1002/14651858.CD005326.pub2.
96. Sabbagh, Y. et al. Repression of osteocyte Wnt/beta-catenin signaling is an early event in the progression of renal osteodystrophy. J. Bone Miner. Res. 27, 1757-1772 (2012).
97. Moyer, V. A. Vitamin D and calcium supplementation to prevent fractures in adults: US Preventive Services Task Force recommendation statement. Ann. Intern. Med. 158, 691-696 (2013).
98. Coburn, J. W., Mischel, M. G., Goodman, W. G. & Salusky, I. B. Calcium citrate markedly enhances aluminum absorption from aluminum hydroxide. Am. J. Kidney Dis. 17, 708-711 (1991).
99. Moorthi, R. N., Kandula, P. & Moe, S. M. Optimal vitamin D, calcitriol, and vitamin D analog replacement in chronic kidney disease: To D or not to D: That is the question. Curr. Opin. Nephrol. Hypertens. 20, 354-359 (2011).
100. Tentori, F. et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 70, 1858-1865 (2006).
101. Institute of Medicine Standing Committee. Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride (National Academies Press, 1997).
102. West, S. L., Jamal, S. A. & Lok, C. E. Tests of neuromuscular function are associated with fractures in patients with chronic kidney disease. Nephrol. Dial. Transplant. 27, 2384-2388 (2012).
103. Howe, T. E. et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database of Systematic Reviews, Issue 7. Art. No.: CD000333. http://dx.doi.org/10.1002/14651858.CD000333.pub2.
104. Li, M., Tomlinson, G., Naglie, G., Cook, W. L. & Jassal, S. V. Geriatric comorbidities, such as falls, confer an independent mortality risk to elderly dialysis patients. Nephrol. Dial. Transplant. 23, 1396-1400 (2008).
105. Desmet, C., Beguin, C., Swine, C. & Jadoul, M. Falls in hemodialysis patients: Prospective study of incidence, risk factors, and complications. Am. J. Kidney Dis. 45, 148-153 (2005).
106. Robling, A. G. et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of sost/sclerostin. J. Biol. Chem. 283, 5866-5875 (2008).
107. Jackson, A. et al. Gene array analysis of Wnt-regulated genes in C3H10T1/2 cells. Bone 36, 585-598 (2005).
108. van Lierop, A. H. et al. Patients with sclerosteosis and disease carriers: Human models of the effect of sclerostin on bone turnover. J. Bone Miner. Res. 26, 2804-2811 (2011).
109. Thambiah, S. et al. Circulating sclerostin and dickkopf 1 (DKK1) in predialysis chronic kidney disease (CKD): Relationship with bone density and arterial stiffness. Calcif. Tissue Int. 90, 473-480 (2012).
110. Atkins, G. J. et al. Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE ASARM dependent mechanism. J. Bone Miner. Res. 26, 1425-1436 (2011).
111. Rhee, Y. et al. Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor 23 in vitro and in vivo. Bone 49, 636-643 (2011).
112. Ryan, Z. C. et al. Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium. Proc. Natl Acad. Sci. USA 110, 6199-6204 (2013).
113. McClung, M. R., Grauer, A., Boonen, S. & Brown, J. P. Inhibition of sclerostin with AMG 785 in postmenopausal women with low bone mineral density: Phase 2 trial results [abstract 1052, online]. http://www.asbmr.org/Meetings/ AnnualMeeting/AbstractDetail.aspx?aid=9fa27a06 d9b5 4429 a95f 517048985173 (2012).
114. Hudson, B., Loots, G., Hum, N. & Thomas, C. SOST inhibits prostate cancer invasion [abstract 1086, online]. http://www.asbmr.org/Meetings/ AnnualMeeting/AbstractDetail.aspx?aid=1ae8843c 167d 4945 9cc8 cc8398018b96 (2012).
115. Shalhoub, V. et al. Chondro/osteoblastic and cardiovascular gene modulation in human artery smooth muscle cells that calcify in the presence of phosphate and calcitriol or paricalcitol. J. Cell Biochem. 111, 911-921 (2010).
116. Roman-Garcia, P. et al. High phosphorus diet induces vascular calcification, a related decrease in bone mass and changes in the aortic gene expression. Bone 46, 121-128 (2010).
117. Wang, D., Dai, C., Li, Y. & Liu, Y. Canonical Wnt/beta-catenin signaling mediates transforming growth factor beta1 driven podocyte injury and proteinuria. Kidney Int. 80, 1159-1169 (2011).
118. He, W. et al. Wnt/beta-catenin signaling promotes renal interstitial fibrosis. J. Am. Soc. Nephrol. 20, 765-776 (2009).
119. Ix, J. H. et al. Fibroblast growth factor 23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J. Am. Coll. Cardiol. 60, 200-207 (2012).
120. Young, A. et al. Bone and mineral metabolism and fibroblast growth factor 23 levels after kidney donation. Am. J. Kidney Dis. 59, 761-769 (2011).
121. Siomou, E. et al. Serum osteoprotegerin, RANKL and fibroblast growth factor 23 in children with chronic kidney disease. Pediatr. Nephrol. 26, 1105-1114 (2011).
122. FDA. Drugs@FDA [online], http://www.accessdata.fda.gov/scripts/cder/ drugsatfda.